DDInter1581 DDInter119
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Repaglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Repaglinide {u} (Compound) binds {v} (Gene) ABCC8
Repaglinide {u} (Compound) is included by {v} (Pharmacologic Class) Potassium Channel Antagonists
Repaglinide {u} (Compound) downregulates {v} (Gene) DNMT3A
Repaglinide {u} (Compound) causes {v} (Side Effect) Ischaemia
Repaglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Repaglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxandrolone
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bempedoic acid
Repaglinide {u} may lead to a major life threatening interaction when taken with {v} Gemfibrozil
Repaglinide (Compound) treats type 2 diabetes mellitus (Disease)
Repaglinide (Compound) binds ABCC8 (Gene)
Repaglinide (Compound) is included by Potassium Channel Antagonists (Pharmacologic Class)
Repaglinide (Compound) downregulates DNMT3A (Gene)
Repaglinide (Compound) causes Ischaemia (Side Effect)
Repaglinide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Repaglinide may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bempedoic acid
Repaglinide may lead to a major life threatening interaction when taken with Gemfibrozil